SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — James Madison

PatientJames Madison
Date of birth2003-03-16
IdentifiersMRN HR-EN007-SYN; SSN (made up) 000-07-2618
Document date2026-04-30
AuthorJosiah Pembroke-Achebe, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Discharge-day review after video-EEG monitoring; epilepsy and functional neurological disorder consultation today. [S]

History of Present Illness

Mr. Madison is seen on the morning of discharge after 72 hours of video-EEG monitoring. Two of his usual events were recorded, the second on the third evening after a night of sleep deprivation, and he confirmed on review of the video that both were typical. His MRI last week was normal. Dr. Okafor-Haverford of neurology reviewed the recordings with him yesterday and explained the diagnosis, and the neuropsychiatric assessment on the unit found generalized anxiety and a moderate depressive episode. He says he is relieved that it is not epilepsy, though he wonders how something that feels so real could come from the mind; he asked good questions and has read the written explanation. He has had no thoughts of death or self-harm, and the rifle has been locked away with the ammunition stored separately since his first visit. He has not driven since then. [S]

ElementDetail
Video-EEGTwo habitual events captured; normal EEG throughout both
MRINormal
Mood and anxietyPHQ-9 12; GAD-7 13
SafetyNo suicidal thoughts; rifle locked; not driving

Review of Systems

SystemResultFinding
ConstitutionalPositiveTired after a night of sleep deprivation; no fever
CardiovascularNegativeNo palpitations, chest pain, or exertional faintness
NeurologicalPositiveTwo recorded events; no headache, weakness, or numbness
PsychiatricPositiveLow mood, worry, and irritability on levetiracetam; no suicidal thoughts, elevated mood, or psychotic symptoms

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Levetiracetam 500 mg oral tablet, one tablet twice daily, started at an emergency department visit four months before intake for possible seizures, without an EEGOne tablet twice dailyOral route2025-12-02 to 2026-04-30completedS
Levetiracetam 500 mg oral tablet, taper: half a tablet (250 mg) twice daily for two weeks, then half a tablet at night for one week, then stopHalf a tablet twice daily for two weeks, then half a tablet at night for one week, then stopOral route2026-04-30 to 2026-05-21completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-04-30Body height168cmS
2026-04-30Body weight54.2kgS
2026-04-30Body mass index (BMI) [Ratio]19.2kg/m2S
2026-04-30Systolic blood pressure110mm[Hg]S
2026-04-30Diastolic blood pressure68mm[Hg]S
2026-04-30Heart rate72/minS
2026-04-30Respiratory rate14/minS
2026-04-30Body temperature36.6CelS
2026-04-30Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-04-30Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]12{score}S
2026-04-30Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]13{score}S

Physical Exam

Vital signs recorded on 2026-04-30; see the Vital Signs section. [S]

SystemFinding
GeneralSlight, tired, engaged
NeurologicalNormal cranial nerves, strength, reflexes, coordination, and gait
Mental statusMood "relieved but low"; affect constricted, brightening when discussing his studies; logical; no suicidal ideation; insight good

Problems

ProblemClinical statusVerificationCodeProvenance
Recurrent sudden episodes of unresponsiveness for two years, two or three a month: he 'blanks out', stops speaking, slumps or sinks to the floor with his eyes closed for two to ten minutes, and afterwards is tearful and tired, with no tongue biting, incontinence, or injury; first during a period of overwork and little sleep at college; with low mood and anxiety; unchanged on levetiracetam; under evaluation for epilepsy, functional (dissociative) seizures, syncope, and other causesresolvedconfirmed R40.4S — Synthetic presenting problem echoing his documented overwork, infirm health, and low spirits, and the later accounts of sudden attacks; superseded by the diagnosis at the second visit.
Taking an antiseizure medicine (levetiracetam) started without a confirmed diagnosis of epilepsyactiveconfirmed Z79.899S — Synthetic medication problem for teaching about avoiding unneeded antiseizure medicines; resolved when the medicine was stopped.
Functional/dissociative seizures (psychogenic nonepileptic seizures), documented by video-EEG: two habitual events captured with eyes closed and resisting opening, fluctuating unresponsiveness, and a normal waking EEG throughout, with no ictal or postictal change; normal interictal EEG and brain MRI; epilepsy and syncope excludedactiveconfirmed F44.5S — Synthetic modern diagnosis. His infirm health, overwork, and low spirits in youth are documented (D); retrospective explanations of his later attacks, including epilepsy, are disputed (R). This record does not assert what his attacks were.
Generalized anxiety disorder: worry about his future, his health, and his studies most days for more than a year, with restlessness, poor sleep, and muscle tension (GAD-7 14 at intake)activeconfirmed F41.1S — Synthetic diagnosis made at the neuropsychiatric assessment during video-EEG monitoring.
Major depressive disorder, single episode, moderate: low mood, loss of interest, poor sleep and concentration, and a sense that he will not live long, for about eighteen months (PHQ-9 13 at intake); no suicidal ideation or intentactiveconfirmed F32.1S — Synthetic diagnosis echoing, without asserting, his documented letter expecting an early death.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
SurveyPHQ-9Baseline, then at least monthly during acute treatment; every 2 to 4 weeks in continuationCompleted today12, down from 13; item 9 scored 0
SurveyGAD-7With the PHQ-9 when anxiety accompanies depressionCompleted today13, down from 14
SurveySuicide risk reassessment (C-SSRS Since Last Visit and PHQ-9 item 9)Every visit during active treatmentCompleted todayNo suicidal thoughts, intent, plan, or behavior; rifle locked with ammunition separate; protective factors unchanged
SurveyBipolar screen at the initial depression workupOnce, at the initial workupCompleted todayNo past manic or hypomanic episode on interview; no Mood Disorder Questionnaire score recorded
ImagingVideo-EEG monitoring to capture habitual eventsOnce, to establish the diagnosisCompleted todayTwo habitual events with a normal EEG throughout; normal interictal EEG; ILAE 'documented' level
ImagingBrain MRI with an epilepsy protocolOnce, in the diagnostic workupCompleted todayNormal, last week
ExaminationEvent diary: frequency, duration, triggers, warning sensations, and injuriesEvery visitCompleted todayTwo or three events a month before admission; two recorded on the unit
Medication safetyAntiseizure medicine reviewAt diagnosis and until withdrawnCompleted todayLevetiracetam without benefit and with irritability; taper over three weeks begins today
Medication safetySSRI tolerability check two weeks after starting2 weeks after starting and after each dose changeNot indicatedNo antidepressant started; psychotherapy first
ReferralNeurology consultation (epilepsy and functional neurological disorder)For recurrent events of uncertain causeCompleted todaySeen on the unit; diagnosis made and explained
ReferralCBT-informed psychotherapy for functional seizuresOnce the diagnosis is acceptedOrderedTwelve weekly sessions starting in two weeks
Self-managementDrivingEvery visit until clearedCompleted todayNot driving; not during the taper; may resume after at least three months free of events, with the neurologist's agreement
Self-managementSleep, studies, and first-aid planEvery visitCompleted todayFixed bedtime with at least seven hours; first-aid card for friends and his tutoring workplace
LaboratoryLithium, anticonvulsant mood-stabilizer, or antipsychotic monitoringOnly on those drugsNot indicatedNot taking any; no bipolar features

Goal progress:

Guideline basis: CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026); LaFrance WC Jr, et al. Minimum requirements for the diagnosis of psychogenic nonepileptic seizures: a staged approach: a report from the International League Against Epilepsy Nonepileptic Seizures Task Force. Epilepsia 2013;54(11):2005-2018 (PMID 24111933) (2013); Hingray C, et al. Functional/dissociative seizures: Proposal for a new diagnostic label and definition by the ILAE task force. Epilepsia 2025;66(11):4162-4182 (PMID 40884444) (2025); Fisher RS, et al. Operational classification of seizure types by the International League Against Epilepsy. Epilepsia 2017;58(4):522-530 (PMID 28276060) (2017); Hall-Patch L, et al. Acceptability and effectiveness of a strategy for the communication of the diagnosis of psychogenic nonepileptic seizures. Epilepsia 2010;51(1):70-78 (PMID 19453708) (2010); Stone J, et al. Explanation as treatment for functional neurologic disorders. Handb Clin Neurol 2016;139:543-553 (PMID 27719870) (2016); LaFrance WC Jr, et al. Multicenter pilot treatment trial for psychogenic nonepileptic seizures: a randomized clinical trial. JAMA Psychiatry 2014;71(9):997-1005 (PMID 24989152) (2014); Goldstein LH, et al. Cognitive behavioural therapy for adults with dissociative seizures (CODES): a pragmatic, multicentre, randomised controlled trial. Lancet Psychiatry 2020;7(6):491-505 (PMID 32445688) (2020); Tolchin B, et al. Seizures, Driver Licensure, and Medical Reporting Update: An AAN Position Statement. Neurology 2025;104(7):e213459 (PMID 40073306) (2025); VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024)

Follow-up: Six-week review; psychotherapy starts in two weeks; call sooner for events that differ from his usual ones, injury, or any thoughts of self-harm. Next scheduled visit 2026-06-11: six-week review after the diagnosis: levetiracetam withdrawn, psychotherapy under way, mood and anxiety. [S]